Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar SorrySam (73.24) Submitted: 12/7/2011 12:50:35 AM : Outperform Start Price: $9.39 HALO Score: -16.48

QVT Financial

Featured Broker Partners


Advertisement